Sign in Register

Drug class

Agents to Treat Erectile Dysfunction, cGMP-Type

The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil. Read more about Agents to Treat Erectile Dysfunction, cGMP-Type

133 drugs in this class 68 manufacturers

Related classes & indications

Iron Chelating AgentsOther therapeutic classes · 45 prescription drugs Phosphodiesterase-4 (PDE4) inhibitorsOther therapeutic classes · 20 prescription drugs Pulmonary Arterial HypertensionTop indication · 135 prescription drugs

Showing 28–36 of 133 drugs

Sort

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

TRUPHARMA, LLC.

VARDENAFIL HCL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

Lannett Company

VARDENAFIL HCL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

TEVA USA

VARDENAFIL HCL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

ZYDUS PHARMACEU

VARDENAFIL HCL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

ALEMBIC PHARMAC

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM ·+1

AJANTA PHARMA L

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM ·+1

UNICHEM PHARMAC

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM ·+1

CAMBER PHARMACE

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM ·+1

BUREL PHARMACEU

Filter & compare in the drug finder → Opens the drug finder with Agents to Treat Erectile Dysfunction, cGMP-Type preselected. Add indication or manufacturer filters there.

About Agents to Treat Erectile Dysfunction, cGMP-Type.

The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil.

These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal.

While formulated primarily as first-line oral therapies for erectile dysfunction, agents within this broader mechanistic family are also utilized to treat pulmonary arterial hypertension and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

fda.gov
The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil
wikipedia.org
The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil
nih.gov
The classification "Agents to Treat Erectile Dysfunction, cGMP-Type" represents a descriptive, compendial or formulary categorization rather than a standard pharmacological class name, corresponding clinically to cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil
fda.gov
These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal
fda.gov
These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal
rigicon.com
These medications act by selectively inhibiting the PDE5 enzyme in the smooth muscle of the corpus cavernosum, preventing the degradation of cGMP and amplifying nitric oxide–mediated vasodilation and penile blood flow during sexual arousal While formulated primarily as first-line oral therapies for erectile dysfunction, agents within this broader mechanistic family are also utilized to treat pulmonary arterial hypertension and lower urinary tract symptoms secondary to benign prostatic hyperplasi...
nih.gov
While formulated primarily as first-line oral therapies for erectile dysfunction, agents within this broader mechanistic family are also utilized to treat pulmonary arterial hypertension and lower urinary tract symptoms secondary to benign prostatic hyperplasia